Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE: DNTH103 in Adult CIDP
CTR20251892Phase 3Active
- Sponsor
- YuanYi Biotech
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by YuanYi Biotech. Started Sep 2025; status: active.
02
Drugs
claseprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on CTR20251892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251892.